MedTrace Logo

LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients

NCT02164903 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 323

Last updated 2018-08-06

No results posted yet for this study

Summary

The broad goal of this study is to investigate if differences exist (and in which areas and of what magnitude) in QoL and symptoms of patients with CML being treated with first line therapy with dasatinib versus those receiving first line therapy with imatinib. Also, an additional objective is to characterize medication-taking behavior associated with imatinib or dasatinib.

Conditions

  • Chronic Myeloid Leukemia

Interventions

OTHER

QoL Survey Booklet

Sponsors & Collaborators

  • European Leukemia Net

    collaborator UNKNOWN

  • CML Advocates Network

    collaborator UNKNOWN

  • Gruppo Italiano Malattie EMatologiche dell'Adulto

    lead OTHER

Principal Investigators

  • Fabio Efficace, PhD · Gruppo Italiano Malattie EMatologiche dell'Adulto

  • Gianantonio Rosti, Dr. · University of Bologna

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-11
Primary Completion
2017-01-25
Completion
2018-10-31

Countries

  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02164903 on ClinicalTrials.gov